Two studies published in Nature found stem-cell derived products can not only be safely transplanted into the brain, but also ...

The advisory committee, which met Tuesday for the first time since Robert F. Kennedy Jr. was sworn in as health secretary, ...

The president’s executive order promising to lower pharmaceutical prices includes support for a fix long sought by the ...

The biotech is developing an experimental drug for the most common of a family of disorders all caused by errors in ...

After a lengthy regulatory back-and-forth, Eisai and Biogen's Alzheimer's drug is on the market in Europe. Elsewhere, Sandoz is alleging Amgen's patent actions were anticompetitive.

This blog delves into the rise of rare disease drug approvals and the critical importance of regulatory guidance in shaping ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...

While J&J expects tariffs will cost it $400 million this year, the company maintained its earnings estimate and upped its ...

As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of U.S.

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

The Atlas-backed company plans to liquidate its assets, including an experimental drug for chronic spontaneous urticaria it ...

The initiative, which will start with monoclonal antibodies, is the first big regulatory shift from the FDA since Martin ...